Abstract 2989
Background
Past and recent findings indicate that adverse effects of chemotherapy influence the patients’ quality of life. The aim of this study was to investigate the implicated factors that influenced the perceived symptoms and quality of life in cancer patients during chemotherapy.
Methods
A longitudinal study was conducted in a large hospital in a major city of Northern Greece. A total of 200 cancer patients undergoing chemotherapy in cycle 2 and cycle 3 were participated in the research. Data was collected using Memorial Symptom Assessment Scale (MSAS), Functional Assessment Cancer Therapy (FACT-G) additionally with a questionnaire for the demographic and clinical characteristics. Descriptive and conductive statistical methods were applied.
Results
The vast majority of the participants were middle aged (58.94±9.94 years) men (n = 122, 61%) suffering from lung cancer (n = 98, 48%). Analysis based on the chemotherapy cycle status revealed a significant differences in several factors grouping the patients regarding their chemotherapy cycle status (cycle 2 vs cycle 3). Particularly, feeling nervous level, severity and distress of dizziness and the severity in the way of food tastes [p = 0.014, p = 0.001, p < 0.001, p < 0.001 and p = 0.030, respectively] differed statistically significantly. Moreover, multiple logistic regression analysis revealed that gender (p < 0.001) and physical well-being score (p = 0.005) affected perceived symptoms in MSAS. Furthermore, gender, occupational status, diet, type of cancer and family status influenced the overall quality of life in cycle 2 patients (p = 0.002, p < 0.001, p = 0.002, p < 0.001 and p < 0.001 respectively); however, in cycle 3 patients : gender (p = 0.003), occupational status (p < 0.001), educational status (p < 0.001) and diet (p < 0.001) were referred as the most statistically significant variables that influence the overall quality of life.
Conclusions
In conclusion, we demonstrate that adverse effects of chemotherapy in cancer patients play a critical role for the overall quality of patients’ life. Patients demographic or/ and clinicobiological characteristics seem to influence the appearance of the adverse effects.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3611 - Phase II trial of SM 88 in Non-Metastatic Biochemical Recurrent Prostate Cancer.
Presenter: Benjamin Gartrell
Session: Poster Display session 3
Resources:
Abstract
2492 - A phase 1 study of Ad5 PSA/MUC-1/Brachyury Vaccine in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Presenter: Marijo Bilusic
Session: Poster Display session 3
Resources:
Abstract
3142 - Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand Binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
Presenter: Douglas McNeel
Session: Poster Display session 3
Resources:
Abstract
4327 - Impact of germline mutations in Homologous Recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC)
Presenter: Elena Castro
Session: Poster Display session 3
Resources:
Abstract
3600 - Serum biomarkers of bone metabolism in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with Radium-223 (Ra223): Results from a prospective multicentre study
Presenter: Nuria Romero Laorden
Session: Poster Display session 3
Resources:
Abstract
3742 - Prognostic value of tumor suppression genes (TP53, PTEN, Rb) in metastatic hormone sensitive prostate cancer
Presenter: Miguel Gonzalez Velez
Session: Poster Display session 3
Resources:
Abstract
2643 - Germline sequencing of advanced prostate cancer patients in the BARCODE2 trial
Presenter: Sarah Benafif
Session: Poster Display session 3
Resources:
Abstract
4349 - Impact of treatment sequence in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): data from the prospective PROREPAIR-B study.
Presenter: Carlo Cattrini
Session: Poster Display session 3
Resources:
Abstract
3301 - Implications of Single Nucleotide Polymorphisms (SNPs) in Androgen Related-Genes in Outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with Abiraterone (Abi) and Enzalutamide (Enza)
Presenter: Isabel Aragon
Session: Poster Display session 3
Resources:
Abstract
2275 - Activating mutations in AKT1/PIK3CA are associated with poor clinical outcomes in metastatic prostate cancer (mPC)
Presenter: Simon Fu
Session: Poster Display session 3
Resources:
Abstract